Bronchiolitis Obliterans Syndrome
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
OrphAI TherapeuticsLAM-001
UNION therapeuticsRuxolitinib
IncyteItacitinib
Clinical Trials (3)
Total enrollment: 103 patients across 3 trials
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
Start: Aug 2023Est. completion: Dec 202630 patients
Phase 2Recruiting
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
Start: Jun 2022Est. completion: Jan 202550 patients
Phase 2Unknown
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
Start: Feb 2020Est. completion: Oct 202323 patients
Phase 1/2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 103 patients
Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.